1. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC)/ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.

2. Барях Е.А. Лимфома Беркитта//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 80 - 87.

3. A.M. et al. Development of hematopoietic stem cell activity in the mouse embryo//Immunity. 1994. Vol. 1, N 4. P. 291 - 301.

4. Melchers F. The pre-B-cell receptor: Selector of fitting immunoglobulin heavy chains for the B-cell repertoire//Nature Reviews Immunology. 2005. Vol. 5, N 7. P. 578 - 584.

5. Van Zelm M.C. et al. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion//J. Exp. Med. 2007. Vol. 204, N 3. P. 645 - 655.

6. Chen J. et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus//Int. Immunol. 1993. Vol. 5, N 6. P. 647 - 656.

7. Teng G., Papavasiliou F.N. Immunoglobulin Somatic Hypermutation//Annu. Rev. Genet. Annual Reviews, 2007. Vol. 41, N 1. P. 107 - 120.

8. Yuan D. Regulation of IgM and IgD synthesis in B lymphocytes. II. Translational and post-translational events.//J. Immunol. 1984. Vol. 132, N 3. P. 1566 - 1570.

9. Natkunam Y. The biology of the germinal center.//Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2007. P. 210 - 215.

10. Raghavan S.C., Hsieh C.-L., Lieber M.R. Both V(D)J Coding Ends but Neither Signal End Can Recombine at the bcl-2 Major Breakpoint Region, and the Rejoining Is Ligase IV Dependent//Mol. Cell. Biol. American Society for Microbiology, 2005. Vol. 25, N 15. P. 6475 - 6484.

11. Тумян Г.С. et al. Диффузная B-клеточная крупноклеточная лимфома//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 58 - 68.

12. Программное лечение заболеваний системы крови: Сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В.Г. Савченко. 2012. 1056 p.

13. Савченко В.Г., Паровичникова Е.Н. Острые лейкозы//Клиническая онкогематология: руководство для врачей. Под ред. Волковой М.А. 2-е изд., перераб. и доп. 2007. P. 409 - 502.

14. Burkitt D.P. The discovery of Burkitt's lymphoma.//Cancer. 1983. Vol. 51, N 10. P. 1777 - 1786.

15. Zelenetz A.D. et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5.2019.

16. Grommes C., DeAngelis L.M. Primary CNS lymphoma//Journal of Clinical Oncology. American Society of Clinical Oncology, 2017. Vol. 35, N 21. P. 2410 - 2418.

17. Демина Е.А. et al. Общие принципы диагностики лимфом//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 9 - 27.

18. Tilly H. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015. Vol. 26 Suppl 5. P. v116 - 25.

19. Kuderer N.M. et al. A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality//Oncologist. Alphamed Press, 2016. Vol. 21, N 7. P. 861 - 867.

20. Santi R.M. et al. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL)//Thromb. Res. Elsevier BV, 2016. Vol. 140. P. S177.

21. Zhuang Y. et al. [Autoimmune hemolytic anemia associated with B-cell chronic lymphoproliferative disorders].//Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013. Vol. 21, N 3. P. 633 - 636.

22. Sumi M. et al. [Primary diffuse large B-cell lymphoma of the bone marrow complicated with autoimmune hemolytic anemia and erythroid hypoplasia].//Rinsho. Ketsueki. 2007. Vol. 48, N 7. P. 571 - 575.

23. Wan S.-G. et al. Incipient Coombs' test negative autoimmune hemolytic anemia precedes non-Hodgkin's lymphoma.//Zhongguo shi yan xue ye xue za zhi. 2012. Vol. 20, N 1. P. 97 - 99.

24. Y. et al. Autoimmune hemolytic anemia as presenting manifestation of primary splenic anaplastic large cell lymphoma.//Turk. J. Pediatr. Vol. 48, N 4. P. 354 - 356.

25. Srivastava S., Wood P. Secondary antibody deficiency-causes and approach to diagnosis//Clin. Med. J. R. Coll. Physicians London. 2016.

26. Мухортова О.В. Использование ПЭТ/КТ при лимфопролиферативных заболеваниях//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 168 - 179.

27. Pelosi E. et al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.//Q. J. Nucl. Med. Mol. Imaging. 2011. Vol. 55, N 4. P. 469 - 475.

28. Khan A.B. et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement//Blood. 2013. Vol. 122, N 1. P. 61 - 67.

29. Кузьмин А.А. et al. Первичная лимфома центральной нервной системы//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 87 - 93.

30. Fekri M.S., Zade M.K., Fatehi S. The association of deep vein thrombosis with cancer treatment modality: Chemotherapy or surgery?//Iran. Red Crescent Med. J. Kowsar Medical Publishing Company, 2014. Vol. 16, N 9.

31. Криволапов Ю.А., Леенман Е.Е. Морфологическая диагностика лимфом. КОСТА, Санкт-Петербург, 2006.

32. Бокерия Л.А., Затевахин И.И., Кириенко А.И. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО).//Флебология. 2015. Vol. 4, N 2. P. 3 - 52.

33. Кириенко А.И., Галстян Г.М., Савченко В.Г. Профилактика венозных тромбоэмболических осложнений при лимфопролиферативных заболеваниях//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 268 - 278.

34. Santi R.M. et al. Khorana score and histotype predicts incidence of early venous thromboembolism in Non-Hodgkin lymphomas: A Pooled-Data analysis of 12 clinical trials of fondazione italiana linfomi (FIL)//Thromb. Haemost. Schattauer GmbH, 2017. Vol. 117, N 8. P. 1615 - 1621.

35. Шмаков Р.Г., Демина Е.А. Лимфомы и беременность//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 143 - 150.

36. Coiffier B. et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte//Blood. American Society of Hematology, 2010. Vol. 116, N 12. P. 2040 - 2045.

37. Feugier P. et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d'etude des lymphomes de l'adulte//J. Clin. Oncol. 2005. Vol. 23, N 18. P. 4117 - 4126.

38. Pfreundschuh M. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group//Lancet Oncol. 2006. Vol. 7, N 5. P. 379 - 391.

39. Miller T.P. et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma//N. Engl. J. Med. 1998. Vol. 339, N 1. P. 21 - 26.

40. Horning S.J. et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484//J. Clin. Oncol. 2004. Vol. 22, N 15. P. 3032 - 3038.

41. Persky D.O. et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014//J. Clin. Oncol. 2008. Vol. 26, N 14. P. 2258 - 2263.

42. T. et al. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study.//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018. Vol. 29, N 8. P. 1882 - 1883.

43. Cunningham D. et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles//Lancet. Lancet Publishing Group, 2013. Vol. 381, N 9880. P. 1817 - 1826.

44. Kwon J. et al. Additional survival benefit of involved-lesion radiation therapy after r-chop chemotherapy in limited stage diffuse large b-cell lymphoma//Int. J. Radiat. Oncol. Biol. Phys. Elsevier Inc., 2015. Vol. 92, N 1. P. 91 - 98.

45. Illidge T. et al. Modern radiation therapy for nodal non-hodgkin lymphoma - Target definition and dose guidelines from the international lymphoma radiation oncology group//International Journal of Radiation Oncology Biology Physics. Elsevier Inc., 2014. Vol. 89, N 1. P. 49 - 58.

46. Held G. et al. Role of radiotherapy to bulky disease in elderly patients with aggressive b-cell lymphoma//J. Clin. Oncol. American Society of Clinical Oncology, 2014. Vol. 32, N 11. P. 1112 - 1118.

47. Shi Z. et al. Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma//Leukemia and Lymphoma. 2013. Vol. 54, N 10. P. 2122 - 2130.

48. Boyle J. et al. Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy.//Oncology (Williston Park). 2014. Vol. 28, N 12. P. 1074 - 1081, 1084.

49. Dabaja B.S. et al. Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project//Cancer. John Wiley and Sons Inc., 2015. Vol. 121, N 7. P. 1032 - 1039.

50. Martino R. et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study.//Haematologica. Haematologica, 2002. Vol. 87, N 8. P. 822 - 827.

51. Zaja F. et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma//Leuk. Lymphoma. 2006. Vol. 47, N 10. P. 2174 - 2180.

52. Moccia A.A. et al. R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.//Blood. American Society of Hematology, 2009. Vol. 114, N 22. P. 408 - 408.

53. Fields P.A. et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: A United Kingdom National Cancer Research Institute trial//J. Clin. Oncol. American Society of Clinical Oncology, 2014. Vol. 32, N 4. P. 282 - 287.

54. Han S.M. et al. Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture//J. Chinese Med. Assoc. Elsevier (Singapore) Pte Ltd, 2008. Vol. 71, N 4. P. 210 - 213.

55. Salles G. et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience//Advances in Therapy. 2017. Vol. 34, N 10. P. 2232 - 2273.

56. Raefsky E.L. et al. Brief duration rituximab(R)/chemotherapy (CNOP or CVP) followed by maintenance rituximab in elderly/poor performance status patients (pts) with diffuse large B-cell lymphoma (DLBCL): A phase II trial of the Minnie Pearl Cancer Research Network//J. Clin. Oncol. American Society of Clinical Oncology, 2006. Vol. 24, N 18_suppl. P. 7577 - 7577.

57. R. et al. Practical aspects of the use of intrathecal chemotherapy Aspectos de la de quimioterapia intratecal//Farm Hosp. 2017. Vol. 41, N 1. P. 105 - 129.

58. Perry C. et al. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study//Am. J. Hematol. Wiley-Liss Inc., 2019. Vol. 94, N 9. P. 992 - 1001.

59. Peyrade F. et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial//Lancet Oncol. 2011. Vol. 12, N 5. P. 460 - 468.

60. Peyrade F. et al. Long-term follow-up of the GELA LNH 03-7B study: A prospective phase II study of 150 patients over 80 years with diffuse large B-cell lymphoma (DLBCL) treated with RminiCHOP.//J. Clin. Oncol. American Society of Clinical Oncology, 2013. Vol. 31, N 15_suppl. P. 8536.

61. Laribi K. et al. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma//Ann. Hematol. Springer Verlag, 2016. Vol. 95, N 10. P. 1705 - 1714.

62. Arakaki H. et al. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma//Annals of Hematology. Springer Verlag, 2017. Vol. 96, N 7. P. 1225 - 1226.

63. Zeremski V. et al. Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study//Ann. Hematol. Springer, 2019. Vol. 98, N 12. P. 2729 - 2737.

64. Storti S. et al. Rituximab plus bendamustine as front-line treatment in frail elderly (> 70 years) patients with diffuse large b-cell non-hodgkin lymphoma: A phase ii multicenter study of the fondazione italiana linfomi//Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, N 8. P. 1345 - 1350.

65. Zinzani P.L. et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: A retrospective study//Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, N 5. P. 381 - 385.

66. Вернюк М.А. et al. Опыт лечения первичной медиастинальной B-крупноклеточной лимфомы//Онкогематология. 2013. Vol. 4. P. 18 - 23.

67. Тумян Г.С. Первичная медиастинальная B-крупноклеточная лимфома: диагностика, клиническая картина и лечение//Современная онкология. 2008. Vol. 10, N 3. P. 66 - 68.

68. Dunleavy K. et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma//N. Engl. J. Med. Massachussetts Medical Society, 2013. Vol. 368, N 15. P. 1408 - 1416.

69. Chan E.H.L. et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma//Cancer Med. Blackwell Publishing Ltd, 2019. Vol. 8, N 10. P. 4626 - 4632.

70. Мангасарова Я.К. et al. Первичная медиастинальная (тимическая) B-крупноклеточная лимфома: диагностика отдаленных экстрамедиастинальных поражений и возможности лечения//Клиническая онкогематология. 2018. Vol. 11, N 3. P. 220 - 226.

71. Derenzini E. et al. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 01) diffuse large B-cell lymphoma//Leuk. Lymphoma. Taylor & Francis, 2009. Vol. 50, N 11. P. 1824 - 1829.

72. Thiel E. et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial//Lancet Oncol. 2010. Vol. 11, N 11. P. 1036 - 1047.

73. Ferreri A.J. et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial//Lancet. 2009. Vol. 374, N 9700. P. 1512 - 1520.

74. Rubenstein J.L. et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)//J. Clin. Oncol. 2013. Vol. 31, N 25. P. 3061 - 3068.

75. Chamberlain M.C., Johnston S.K. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.//Neuro. Oncol. 2010. Vol. 12, N 7. P. 736 - 744.

76. Holdhoff M. et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma//Neurology. Lippincott Williams and Wilkins, 2014. Vol. 83, N 3. P. 235 - 239.

77. Omuro A. et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: An intergroup ANOCEF-GOELAMS randomised phase 2 trial//Lancet Haematol. Elsevier Ltd, 2015. Vol. 2, N 6. P. e251 - e259.

78. Morris P.G. et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome//J. Clin. Oncol. American Society of Clinical Oncology, 2013. Vol. 31, N 31. P. 3971 - 3979.

79. Fritsch K. et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2011. Vol. 22, N 9. P. 2080 - 2085.

80. Wong E.T. et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas//Cancer. 2004. Vol. 101, N 1. P. 139 - 145.

81. Illerhaus G. et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma//J. Clin. Oncol. 2006. Vol. 24, N 24. P. 3865 - 3870.

82. Houillier C. et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.//J. Clin. Oncol. American Society of Clinical Oncology, 2019. Vol. 37, N 10. P. 823 - 833.

83. Ferreri A.J.M. et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial//Lancet Haematol. Elsevier Ltd, 2016. Vol. 3, N 5. P. e217 - e227.

84. Maschan A. et al. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M//Br. J. Haematol. Blackwell Publishing Ltd, 2019. Vol. 186, N 3. P. 477 - 483.

85. Kane E. et al. Emergency admission and survival from aggressive non-Hodgkin lymphoma: A report from the UK's population-based Haematological Malignancy Research Network//Eur. J. Cancer. Elsevier Ltd, 2017. Vol. 78. P. 53 - 60.

86. Senbanjo I.O. Tumor lysis and acute renal failure in Burkitt's lymphoma: A review on pathophysiology and management//Indian Journal of Nephrology. 2009. Vol. 19, N 3. P. 83 - 86.

87. Oosten L.E.M. et al. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.//Ann. Hematol. 2018. Vol. 97, N 2. P. 255 - 266.

88. Dunleavy K. Approach to the Diagnosis and Treatment of Adult Burkitt's Lymphoma//J. Oncol. Pract. American Society of Clinical Oncology (ASCO), 2018. Vol. 14, N 11. P. 665 - 671.

89. Барях Е.А., Мякова Н.В., Поддубная И.В. Профилактика и лечение синдрома лизиса опухоли//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 251 - 253.

90. Барях Е.А. et al. Лейкоз/лимфома Беркитта: клинические особенности, диагностические критерии, терапевтическая тактика//Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2010. Vol. 3, N 2. P. 138 - 143.

91. Дудина Г.А., Пивник А.В. Неходжкинские лимфомы у больных ВИЧ-инфекцией//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 126 - 137.

92. Sweetenham J.W. et al. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma - Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: Results from the European group for blood and marrow transplantation//J. Clin. Oncol. American Society of Clinical Oncology, 1996. Vol. 14, N 9. P. 2465 - 2472.

93. Doocey R.T. et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.//Br. J. Haematol. 2005. Vol. 131, N 2. P. 223 - 230.

94. Guidelines for the management of non--Hodgkin's and Hodgkin's lymphoma in adults. 2015.

95. Velasquez W.S. et al. ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study//J. Clin. Oncol. American Society of Clinical Oncology, 1994. Vol. 12, N 6. P. 1169 - 1176.

96. Zelenetz A.D. et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma//Ann. Oncol. 2003. Vol. 14, N SUPPL. 1.

97. Crump M. et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)//Cancer. 2004. Vol. 101, N 8. P. 1835 - 1842.

98. Corazzelli G. et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.//Cancer Chemother. Pharmacol. 2009. Vol. 64, N 5. P. 907 - 916.

99. Chau I. et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma//Br. J. Haematol. 2001. Vol. 115, N 4. P. 786 - 792.

100. Amorim S. et al. Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment//Leukemia and Lymphoma. Taylor and Francis Ltd, 2016. Vol. 57, N 10. P. 2425 - 2428.

101. Philip T. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin's lymphoma//N. Engl. J. Med. 1995. Vol. 333, N 23. P. 1540 - 1545.

102. Mounier N. et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study Association trial//Haematologica. 2013. Vol. 98, N 11. P. 1726 - 1731.

103. Vacirca J.L. et al. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma//Ann. Hematol. 2014. Vol. 93, N 3. P. 403 - 409.

104. Ohmachi K. et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma//Journal of Clinical Oncology. American Society of Clinical Oncology, 2013. Vol. 31, N 17. P. 2103 - 2109.

105. Chao N.J., Rosenberg S.A., Horning S.J. CEPP(B): An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma//Blood. 1990. Vol. 76, N 7. P. 1293 - 1298.

106. Gopal A.K. et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: A prospective multi-center phase II study by the Puget Sound Oncology Consortium//Leuk. Lymphoma. 2010. Vol. 51, N 8. P. 1523 - 1529.

107. Papageorgiou E.S. et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group//Eur. J. Haematol. 2005. Vol. 75, N 2. P. 124 - 129.

108. McLaughlin P. et al. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma.//J. Natl. Cancer Inst. 1988. Vol. 80, N 17. P. 1408 - 1412.

109. Welch M.R. et al. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide//Leuk. Lymphoma. Informa Healthcare, 2015. Vol. 56, N 2. P. 361 - 367.

110. Nguyen P.L. et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma//J. Clin. Oncol. 2005. Vol. 23, N 7. P. 1507 - 1513.

111. Cheson B.D. et al. Revised response criteria for malignant lymphoma//Journal of Clinical Oncology. 2007. Vol. 25, N 5. P. 579 - 586.

112. Aapro M. et al. Клинические рекомендации по лечению анемии у больных злокачественными новообразованиями. М.: Ассоциация онкологов России, 2014.

113. Орлова Р.В. et al. Практические рекомендации по лечению анемии при злокачественных новообразованиях//Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018. P. 494 - 501.

114. Владимирова Л.Ю. et al. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных//Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018. P. 502 - 511.

115. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями.//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 289 - 311.

116. Meirow D., Nugent D. The effects of radiotherapy and chemotherapy on female reproduction//Hum. Reprod. Update. 2001. Vol. 7, N 6. P. 535 - 543.

117. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.

118. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 278 - 288.

119. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies.//Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.

120. Rozental A. et al. The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis//Hematol. Oncol. John Wiley and Sons Ltd, 2019. Vol. 37, N 1. P. 27 - 34.

121. Румянцев А.Г., Самочатова Е.В. Практическое руководство по детским болезням. Гематология/онкология детского возраста. Медпрактика-М, Москва, 2004.

122. Cheson B.D. et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification//Journal of Clinical Oncology. American Society of Clinical Oncology, 2014. Vol. 32, N 27. P. 3059 - 3067.

123. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma//N. Engl. J. Med. 1993. Vol. 329, N 14. P. 987 - 994.

124. Abdelhamid T. et al. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study//J. Egypt. Natl. Canc. Inst. 2011. Vol. 23, N 1. P. 17 - 24.

125. Abrey L.E. et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma//Journal of Clinical Oncology. 2005. Vol. 23, N 22. P. 5034 - 5043.

126. Yelvington B.J. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma.//J. Adv. Pract. Oncol. Harborside Press, 2018. Vol. 9, N 5. P. 530 - 534.

127. Davies A. et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development//Advances in Therapy. Springer Healthcare, 2017. Vol. 34, N 10. P. 2210 - 2231.

128. R. et al. Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study//Br. J. Haematol. Blackwell Publishing Ltd, 2020. Vol. 188, N 5. P. 661 - 673.

129. Macdonald D. et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma//Current Oncology. Multimed Inc., 2017. Vol. 24, N 1. P. 33 - 39.

130. Gang A.O. et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group.//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2012. Vol. 23, N 1. P. 147 - 153.

131. Thomas D.A. et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia//Cancer. 2006. Vol. 106, N 7. P. 1569 - 1580.

132. Batchelor T. et al. Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96-07//J. Clin. Oncol. American Society of Clinical Oncology, 2003. Vol. 21, N 6. P. 1044 - 1049.

133. Zhu J.-J. et al. High-dose methotrexate for elderly patients with primary CNS lymphoma//Neuro. Oncol. Oxford University Press (OUP), 2009. Vol. 11, N 2. P. 211 - 215.

134. Samochatova E.V. et al. Therapy of advanced-stage mature b-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): The results of a multicenter study//J. Pediatr. Hematol. Oncol. Lippincott Williams and Wilkins, 2014. Vol. 36, N 5. P. 395 - 401.

135. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group//Am. J. Clin. Oncol. 1982. Vol. 5, N 6. P. 649 - 655.

136. Meignan M., Gallamini A., Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma//Leukemia and Lymphoma. 2009. Vol. 50, N 8. P. 1257 - 1260.

137. Khorana A. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis//Blood. 2008. Vol. 111, N 10. P. 4902 - 4907.